Teleflex (TFX)
NYSE: TFX
· Real-Time Price · USD
122.22
-0.31 (-0.25%)
At close: May 30, 2025, 3:59 PM
123.58
1.11%
After-hours: May 30, 2025, 05:16 PM EDT
Teleflex Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anesthesia Revenue | 395.29M | 389.96M | 388.89M | 380.14M | 302.29M | 338.41M | 349.37M | 233.98M | 225.21M | 218.66M | 233.11M | 1.05M |
| Anesthesia Revenue Growth | +1.37% | +0.27% | +2.30% | +25.75% | -10.67% | -3.14% | +49.32% | +3.90% | +3.00% | -6.20% | +22037.42% | n/a |
| Interventional Urology Revenue | 331.09M | 319.79M | 322.83M | 341.66M | 290.02M | 290.45M | 196.74M | n/a | n/a | n/a | n/a | 277.44M |
| Interventional Urology Revenue Growth | +3.54% | -0.94% | -5.51% | +17.81% | -0.15% | +47.63% | n/a | n/a | n/a | n/a | n/a | n/a |
| Interventional Revenue | 586.06M | 511.43M | 445.02M | 427.5M | 382.44M | 427.56M | 395.42M | n/a | n/a | n/a | n/a | n/a |
| Interventional Revenue Growth | +14.59% | +14.92% | +4.10% | +11.78% | -10.55% | +8.13% | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Revenue | 207.22M | 291.9M | 285.15M | 336.58M | 367.26M | 347.27M | 366.85M | n/a | n/a | n/a | n/a | n/a |
| Other Revenue Growth | -29.01% | +2.37% | -15.28% | -8.35% | +5.75% | -5.34% | n/a | n/a | n/a | n/a | n/a | n/a |
| Surgical Revenue | 450.48M | 427.36M | 392.92M | 377.76M | 317.2M | 370.07M | 358.71M | n/a | n/a | n/a | n/a | n/a |
| Surgical Revenue Growth | +5.41% | +8.77% | +4.01% | +19.09% | -14.29% | +3.17% | n/a | n/a | n/a | n/a | n/a | n/a |
| Vascular Access Revenue | 732.67M | 708.04M | 683.61M | 700.24M | 657.7M | 600.87M | 575.33M | n/a | n/a | n/a | n/a | n/a |
| Vascular Access Revenue Growth | +3.48% | +3.57% | -2.37% | +6.47% | +9.46% | +4.44% | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asia Revenue | 326.37M | 346.9M | 306.32M | 297.77M | 267.02M | 241.28M | 286.89M | 269.21M | 249.42M | 241.73M | 237.7M | 207.21M | 789.77M | 799.34M |
| Asia Revenue Growth | -5.92% | +13.25% | +2.87% | +11.52% | +10.67% | -15.90% | +6.57% | +7.94% | +3.18% | +1.70% | +14.71% | -73.76% | -1.20% | n/a |
| Emea Revenue | 705.09M | 586.25M | 558.37M | 606.81M | 584.86M | 652.07M | 603.81M | 552.72M | 510.93M | 514.44M | 593.07M | 557.43M | n/a | n/a |
| Emea Revenue Growth | +20.27% | +4.99% | -7.98% | +3.75% | -10.31% | +7.99% | +9.24% | +8.18% | -0.68% | -13.26% | +6.39% | n/a | n/a | n/a |
| United States Revenue | 1.89B | n/a | n/a | n/a | n/a | 1.61B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| United States Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Sep 25, 2022 | Jun 26, 2022 | Mar 27, 2022 | Dec 31, 2021 | Sep 26, 2021 | Jun 27, 2021 | Mar 28, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 31, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Sep 25, 2016 | Jun 26, 2016 | Mar 27, 2016 | Dec 31, 2015 | Sep 27, 2015 | Jun 28, 2015 | Mar 29, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 222.71M | 254.55M | 247.26M | 250.63M | 242.83M | 260.65M | 213.19M | 223.31M | 232.72M | 233.38M | 208.62M | 216.93M | 203.93M | 227.58M | 205.19M | 224.16M | 203.15M | 232.91M | 171.67M | 191.19M | 147.8M | 240.6M | 229.9M | 236.19M | 227.69M | 218.54M | 214.89M | 229.92M | 215.34M | 213.29M | 163.77M | 158.93M | 163.97M | 144.18M | 139.8M | 142.98M | 136.35M | 148.22M | 138.84M | 142.23M | 139.7M |
| Selling, General, and Administrative Revenue Growth | -12.51% | +2.95% | -1.35% | +3.21% | -6.84% | +22.26% | -4.53% | -4.04% | -0.28% | +11.87% | -3.83% | +6.37% | -10.39% | +10.91% | -8.46% | +10.34% | -12.78% | +35.67% | -10.21% | +29.36% | -38.57% | +4.66% | -2.66% | +3.73% | +4.19% | +1.70% | -6.53% | +6.77% | +0.96% | +30.24% | +3.04% | -3.07% | +13.73% | +3.14% | -2.23% | +4.87% | -8.01% | +6.75% | -2.38% | +1.81% | n/a |
| Research and Development Revenue | 36.4M | 44.55M | 38.73M | 41.09M | 37.3M | 35.86M | 37.58M | 39.45M | 41.47M | 42.76M | 37.77M | 36.93M | 36.36M | 35.8M | 31.82M | 33.28M | 29.95M | 33.77M | 29.22M | 29.36M | 27.4M | 31.13M | 27.98M | 27.59M | 27.15M | 27.8M | 26.36M | 26.02M | 26.03M | 25.47M | 21.19M | 20.28M | 17.83M | 15.69M | 15.07M | 15.47M | 12.35M | 13.22M | 12.57M | 13.44M | 12.88M |
| Research and Development Revenue Growth | -18.29% | +15.05% | -5.76% | +10.17% | +4.02% | -4.57% | -4.75% | -4.87% | -3.01% | +13.20% | +2.26% | +1.58% | +1.58% | +12.51% | -4.41% | +11.14% | -11.32% | +15.58% | -0.50% | +7.18% | -11.99% | +11.23% | +1.41% | +1.64% | -2.33% | +5.44% | +1.33% | -0.03% | +2.18% | +20.18% | +4.52% | +13.75% | +13.64% | +4.11% | -2.62% | +25.25% | -6.57% | +5.17% | -6.49% | +4.34% | n/a |